CliffBio
biologic

Emrelis

telisotuzumab vedotin-tllv

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameEmrelis
Active ingredienttelisotuzumab vedotin-tllv
Strength20MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.